| 0.731 0.021 (2.96%) | 05-12 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.89 | 1-year : | 1 |
| Resists | First : | 0.76 | Second : | 0.86 |
| Pivot price | 0.75  |
|||
| Supports | First : | 0.62 | Second : | 0.51 |
| MAs | MA(5) : | 0.7 |
MA(20) : | 0.75 |
| MA(100) : | 0.85 |
MA(250) : | 0.91 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 30.1 |
D(3) : | 20.4 |
| RSI | RSI(14): 47.6 |
|||
| 52-week | High : | 1.7 | Low : | 0.62 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ XLO ] has closed above bottom band by 36.6%. Bollinger Bands are 53.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 9 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.75 - 0.76 | 0.76 - 0.76 |
| Low: | 0.69 - 0.69 | 0.69 - 0.7 |
| Close: | 0.72 - 0.73 | 0.73 - 0.74 |
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.
Thu, 08 May 2025
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results - GlobeNewswire
Thu, 08 May 2025
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results - Stock Titan
Fri, 02 May 2025
Xilio Therapeutics Awards 5,000 Share Stock Option Grant at $0.755 Per Share to New Employee - Stock Titan
Fri, 02 May 2025
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Fri, 04 Apr 2025
Xilio Expands Immuno-Oncology Team: 23K Shares Granted to New Biotech Talent - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 52 (M) |
| Shares Float | 32 (M) |
| Held by Insiders | 28.1 (%) |
| Held by Institutions | 47.7 (%) |
| Shares Short | 351 (K) |
| Shares Short P.Month | 645 (K) |
| EPS | -1.1 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.14 |
| Profit Margin | 0 % |
| Operating Margin | -472.8 % |
| Return on Assets (ttm) | -38.3 % |
| Return on Equity (ttm) | -297.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0.17 |
| Sales Per Share | 0.17 |
| EBITDA (p.s.) | -1.07 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.68 |
| PEG Ratio | 0 |
| Price to Book value | 5.22 |
| Price to Sales | 4.08 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|